Skip to main content

More J&J troubles: Vaccine manufacturing halted and more possible clot cases

posted onApril 19, 2021
by l33tdawg
Arstechnica
Credit: Arstechnica

The US Food and Drug Administration last week asked Emergent BioSolutions to stop making Johnson & Johnson’s COVID-19 vaccine at its troubled facility in Baltimore, according to a regulatory filing Emergent released Monday.

The FDA had begun an inspection of the contract manufacturer’s facility on April 12 but requested on April 16 that production be halted “pending completion of the inspection and remediation of any resulting findings,” the filing reads. Any vaccine materials already made at the plant will be held in quarantine.

The production halt follows news last month that a mishap at the plant led to the ruin of 15 million doses of Johnson & Johnson’s one-shot COVID-19 vaccine. The ruined doses had reportedly been contaminated with ingredients from AstraZeneca’s COVID-19 vaccine, which was also being manufactured at the plant at the time. The accident was a major stumbling block for Johnson & Johnson’s vaccine production—but not a consumer safety issue. All of the doses of Johnson & Johnson’s vaccine that has been used in the US so far have been produced in the Netherlands. The Emergent facility in Baltimore had not yet been authorized by the FDA for vaccine production when the doses were ruined, and none of the spoiled doses completed the production process.

Source

Tags

Industry News

You May Also Like

Recent News

Friday, November 8th

Friday, November 1st

Tuesday, July 9th

Wednesday, July 3rd

Friday, June 28th

Thursday, June 27th

Thursday, June 13th

Wednesday, June 12th

Tuesday, June 11th

Friday, June 7th